|
Overview
THE MOST COMPREHENSIVE COVERAGE OF PROTEIN BIOMARKERS:
Pre-Conference Executive ThinkTank
Case Studies of Proteomic Biomarker Applications (Cancer, CNS, and more...)
Protein Biomarker Discovery and Biological Validation
Assay Development and Analytical Validation
Ideal Proteomic Biomarkers: Identified Proteins vs. Proteome Signatures vs. PTMs
Protein Biomarkers vs. Genomic and Metabolomic Biomarkers
Interactive ThinkTank Roundtable Discussions
New Technology Showcase
Poster and Exhibit Viewing
Networking with Expert Delegates
Speakers from: Abbott Amgen Bayer Eastern Virginia Medical School FDA Geneva Univ. Hospital GlaxoSmithKline Johns Hopkins Univ. Johnson & Johnson Lilly Mayo Clinic McKnight Brain Inst. Novartis Pfizer Plasma Proteome Inst. Roche Van Andel Inst. Wyeth
DISTINGUISHED FACULTY
Dr. Leigh Anderson, Founder & CEO, Plasma Proteome Institute
Dr. Mohan Bangalore, Manager, Biomarker Outsourcing, Human Biomarker Center, GlaxoSmithKline
Dr. Stanley M. Belkowski, Senior Scientist, Target Validation Team, Johnson and Johnson Pharmaceutical Research and Development,
L.L.C.
Dr. John Bilello, Director of Technology Development, Human Biomarker Center, GlaxoSmithKline
Dr. Walter Carney, President, Oncogene Science, Bayer Health Care
Dr. Daniel W. Chan, Director, Biomarker Discovery Center, Johns Hopkins University
Dr. Brian B. Haab, Scientific Investigator, The Van Andel Research Institute
Dr. John E. Hale, Research Advisor, Integrative Biology Division, Lilly Research Labs
Dr. Orest Hurko, Associate Vice President, Discovery Medicine, Wyeth Research
Mr. Francois Legay, Head of Marker and Assay Development, Novartis Pharma
Dr. Michael T. Lotze, Director, Translational Research, Molecular Medicine Institute, University of Pittsburgh School of Medicine
Mr. Thomas Metcalfe, Head of the Roche Biomarker Program, Roche Molecular Systems, Inc.
Dr. David C. Muddiman, Professor of Biochemistry and Molecular Biology, Founder and Director,
W.M. Keck FT-ICR Mass Spectrometry Laboratory, Mayo Clinic College of Medicine
Dr. Stephen Naylor, CSBi and Division of Biological Engineering, MIT; and Dept. of Genetics and
Genomics, Boston University School of Medicine
Dr. Scott D. Patterson, Director of Medical Sciences, Amgen Inc.
Dr. Emanuel F. Petricoin, Co-Director, NCI-FDA Clinical Proteomics Program, Senior Principal Investigator, Center for Biologics Evaluation and Research, U. S. Food and Drug Administration
Dr. Jean-Charles Sanchez, Biomedical Proteomics Research Group, Central Clinical Chemistry Laboratory, Geneva University Hospital
Dr. O. John Semmes, Director, Center for Biomedical Proteomics; and Associate Professor, Dept. of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School
Dr. Jennifer Van Eyk, Institute of Molecular Cardiobiology, Johns Hopkins Univ.
Dr. Jacky Vonderscher, V.P., Global Head of BioMarker Development, Novartis Institutes for BioMedical Research, Inc.
Dr. Kevin K.W. Wang, Director, Center for Neuroproteomics and Biomarkers Research; Scientific Director, Center for Traumatic Brain Injury Studies; and Associate Professor of Department of Psychiatry & Neuroscience, McKnight Brain Institute, University of Florida
Dr. Scott E. Warder, Associate Research Investigator, Proteomics, Abbott Laboratories
Dr. Stephen Williams, Executive Director and Worldwide Head of Clinical, Technology, Pfizer Global Research and Development
|
